Member Info for SocialistB

SP wise, HEMOGENYX is not where it deserve to be with all the positive information we got about HG-CT-1.

Worst case scenario, that won't chance even when the company generates cash with the G-rex system.

But it will, when we manufacture HG-CT-1 .

Keep it inhouse, I say:-)

Yes it did say a two room setup could handle over 100.000 a year, which sounds insane when you do the math with just one robotarm like in the video.

100.000 / 250 days a year (no work on weekends, and allows for 11 days downtime a year) equals 400 a day.

400 units / 8 hours equels 50 an hour.

I doubt that to be possible, even with a robotarm.

But the video did also mention a 2 room setup, then it is only suddenly 25 units an hour.

And if it is possible to have more then 1 robotarm in each cleanroom, the number becomes even smaller.

Awesome.

If this works out to be decent income avenue, then we might be done with placings.

Getting enough money to maintain the remaining employees and maybe even eough to pay for the trials.

Shouldn't be a problem if three is 2-3 months between each injection.

Enough time to hopefully earn the cost.

Go Hemo go

@Saint68

Thank you for your earlier reply.

You have a good valid point.

I hope it's not the case, that someone is building a big position with the intent to make a hostile takeover, but you never know.

I lean more towards the theory that they are building a huge position in warrents and are willing to sell at a loss to stay below the threshold where they have to declare their position.

We will find out one day.

Let's hope it's not your concern that manifests itself:-)

Also, lets not forget another potential important reason and one all LTH should appreciate.

The threshold for notifying the market if you have a certain percentage ownership.

I have heard it so often but am unsure of it's correctness, that there are ways to avoid declaring the percentage, like putting them up for sale or just plainly denying to declare and that the penalty is modest for doing so.

Even if that is correct, then I'll claim it is still better to do those things at this stage, rather then 6 months from now when HEMOGENYX is on everyone's lips.

It just brings a different level of scrutiny.

Currently we only have Hulver on this board that seems to care and be capable of this scrutiny, but that will not remain so.

If later on a company feels they have to declare a significant percentage ownership and then starts to realise profits and inform the market about it then that could have a detrimental effect on the share price.

We should therefore appreciate if someone is hell-bent on staying below the percentage where they have to make declarations.

Even if it is at loss. And has a negative effect on the share price at the moment.

Rather now, then in a rising market.

@Peterpharma

It is not as bizarre as you suggest if you give some extra thought.

The money I have put into this is an investment.

It was not a donation to a charity, that I hope will develop a cure.

So, just like you and I assume everyone else, I want to make a return on my investment here.

I just happen to like the thought of Hemogenyx becoming a major player in the Pharma industry the most.

And the best way to do that, in my view, is to have many sources of income.

And I believe HG-CT-1 will be precisely that.

And I believe it could potentially happen relatively soon, if the efficacy is as good as I hope it will be. (Which is still unknown)

The problem with selling a candidate like HG-CT-1 is that you are always selling it for less than it is worth.

A buyer paying more than it is worth is doing a bad deal, and I see no reason to wish that upon shareholders in another company.

So for them to do a good deal, they have to pay less than its actual worth.

And we are not talking about them getting the deal 20% cheaper, if that was the case, I'd say sign the dotted line straight away and let's get on with CBR.

I find that most of these deals only pay the underdog a fraction of what the product is worth.

So, if we are relatively close to bringing the product to those unlucky enough to contract AML, then I am totally in favour of more dilution as I clearly expect that there is more value for us in being the owner of HG-CT-1 long term, than selling it for a fraction of what it is worth.

Having said that, like you and many others, I do not enjoy sitting on a hefty loss at the moment.

Yes, it has been great to be able to buy shares in a company with one positive medical RNS after another and lower my average, but even I have now reached my limit and would like to see a turnaround.

However, it is just an undesirable path on the journey to the end goal.

It's been weeks since we heard about the manufacturing of car-T cells being initiated for Patient 3, but we have not heard anything since then about Patient 3 being injected.

I would have expected the injection to have taken place already by now.

And maybe it has!

But the market has not been informed.

But if it has not, then it ought to be happening very soon.

And if it doesn't happen very soon, I can't help but wonder if Patient 3's health took a turn for the worse between the start of the manufacturing of HG-CT-1 and the time it was ready.

If that is the case and it has been deemed undesirable/impossible to inject the original Patient 3, then I expect we will soon get a new Patient 3.

@Saint68

Thanks for your feedback.

Yeah, it's exactly reasons like the ones you are mentioning about potential accelerated approval paths and costs in just a few millions to complete phase 1 that makes me think it is actually feasible for us to keep HG-CT-1 in house.

The primary point of a Phase 1 study is to establish the safety of various doses.

We already know that HG-CT-1 is safe and has shown efficacy at the lowest dose which was given to Patient 1 about some 5 months ago.

Should the FDA decide to accelerate approval, it would be a shame to have sold the product so close to the finish line.

So, I say, bring on the dilution needed to get us over the finish line.

@Haywain

Thank you for your answer earlier today.

The AI'ing was not in regard to HEMOGENYX specifically , just a generalisation of what it could potentially cost a small pharma company to develop a candidate, become clinical and complete a phase 1 trial.

And HEMOGENYX have managed to do it significantly below this suggested amount.

They have been financial astute when comes to controlling the cost of development for our candidates, because we do have more then one, we are not a one trick poney so there is much to look forward to over the years to come.

Your answer and suggested sum of potentially just 6 million needed makes me wonder if it would not be best to keep HG-CT-1 for our selves, we have the premises to expand and the agreement with Janus allows us to move to bigger premises within the group without any penalties should that be needed.

Again with your expertise in the field, at what point can we start charging insurance companies for our product, can we do so before finishing phase 3 trials or is it a prerequisite that the trials are completed before we can do so?

The company seems to have cut it's overheads significantly recently.

I think it would be awesome if we could develop it on our own, rather then having to sell, if we are really just a few millions away from being cash generating.

If that's even remotely possible, I say bring on the dilution for a few more months.

Keeping the product in house would totally be worth it.

But is that wish even remotely possible?

@Haywin

Back on the 9th you said:

"Tiered funding from big pharma - every time : small amount up front with big milestone payments and commercial royalties"

Having done some AI'ing on costs of phase 1 trials, I have seen the number 50 million as a possible expense.

That sum is in line with the money we originally got at disposel from a funding source that turned out to be an unfortunate choice.

HEMOGENYX, have managed to get approval of HG-CT-1 and injected 2 patients and FDA clearence to start treating children.

With your knowledge of the sector, do you dare to say if I am spot on claiming that the rest of the phase 1 trial can most likely be done for less then 20 millions?

And that such a sum would not be unreasonable to expect as an upfront payment from a big pharma at the stage we are at, with Patient 1 still alive almost 6 months after the first injection ?

I hate losing a job I care about.

And Mr. Sandler have told in the past how everyone went above and beyond what could be expected of them.

I hate to see good employees be let go.

I hope they can and will be re-hired when the company's fortune turns.

I do not envy Mr. Sandler his position, I would absolutely hate to have to let people go.

But that comes with the job description.

But, I wonder why now?

And as is so often the case, I muse about the strong vs the weak.

Maybe HEMOGENYX are being strong-armed in negotiations.

Are they dragging out.

Have HEMOGENYX been told funds are not freely available as before?

Is that the reason why this cost cutting measure is being made so shortly before we expect positive news.

Lower overheads = more months afloat without a raise.

Talking about which, the de-ramp gang has been out in force this week.

If we see a a raise next week, I think I'll allow myself to speculate that someone had been tipped off and came here to cause trouble.

Anyhow, I iwsh all the best to the people that unfortunately have had to be let go, wish her all the best for the future and thank you for your contribution to the company I have invested in.

Hope to see you onboard in the future

Further funding is needed, there is no doubt about that.

A grant from any kind of organisation would be the dream.

But if that does not happen, then the 4 following are the first that comes to mind.

1. A raise at a discount.

2. A raise with no discount

3. Funds from a VC for X amount f the company or HG-CT-1

4. Funds from a big Pharma on the same terms as above.

At this point in time, I still favour option 2, as I am not certain we will get a fantastic deal from option 3&4 at this stage.

But I wouldn't mind being proven wrong:-)

What's your preferred option?

Dare to dream about the future share price.

Let's asume that we might need a future raising to tie us over a little bit longer and then add in the existing options and I would be surprised if we do not land in the region of some 6 million shares in issue.

However, if HG-CT-1 could be sold, licensed or in any other way be part of a deal worth 2 billion dollars, then that still amount to over 300 dollars a share.

I dream that the vast majority of shareholders recognise that CBR is worth far more then this and refuse to accept a lowball offer for the company in this region.

For HG-CT-1 maybe, but not for the company.

We might already hear about efficacy this month, but it's not a given as all is run by MD Anderson and they might not have or be willing to give out the information at this stage.

But here's to hoping for a fantastic July.

4,593,539 shares in circulation

And that will not be the end of it.

We know there are options to be had as well, if the owners chose to redeem them in the future.

But long before that, there will be further dilution.

Hemogenyx, will most likely need to make another placing in the coming months, to obtain money to carry on the business.

And that is totally legit.

That is maybe the main purpose to be on a stock exchange, when a company is not cash generating.

Of course we could get a deal with a big pharma before we need to raise again (and one day that will be the actual reality)

But money from a big pharma is also dilution.

Question is how good the deal will be?

I am a firm believer that the more clinical data and proof of concept we got, the better a deal we will get.

So, I am all for further needed dliution, necessary to get to that goal.

There is however one thing I am more in favour of:

FREE MONEY.

However, so far that has unfortunately not been a forthcoming option.

It goes to show that such a thing as a free lunch is rare, if existing at all on the first place.

Further funds needed and HEMOGENYX will succeed in getting it.

That is what history tells me.

It is an undeniable fact that HEMOGENYX haso s far always managed to secure funds, you can say they have an unblemished track record in this regard.

And that is something to be appreciate of, because the alternative would be winding ofwn which wouldb e dreadful.

So anyone invested today are invested in a fighter and survivor.

And that is really comforting in a situation where therea s not been the value creation as I had expected according to the textbook.

I might live to regret these words :

Bring on the dilution

(but in moderation and only as needed)

Thanks for the link MrIndia, here isan AI layman explanation of part of the article :

Hemogenyx Pharmaceuticals has made significant strides in developing a new type of cancer treatment called CAR-T therapy, specifically targeting a protein known as FLT3, which is often found in acute myeloid leukemia (AML). Here's a simplified breakdown of what they've achieved:

### What is CAR-T Therapy?

CAR-T therapy is a form of immunotherapy where a patient's own immune cells (T cells) are modified in the lab to better recognize and attack cancer cells. In this case, the focus is on FLT3, a protein that can promote the growth of leukemia cells.

### Key Achievements of Hemogenyx:

1. **Innovative Design**: Hemogenyx has developed a new CAR-T treatment called HEMO-CAR-T. This treatment uses a specially designed antibody that targets FLT3 without competing with a natural protein (FLT3 ligand) that can interfere with the treatment. This means that even when FLT3 ligand levels are high, HEMO-CAR-T can still effectively target and kill leukemia cells.

2. **Safety Features**: The HEMO-CAR-T therapy includes safety mechanisms to reduce the risk of side effects. For example, if the treatment causes severe reactions, there are ways to deactivate the CAR-T cells. This is crucial because CAR-T therapies can sometimes lead to serious side effects like cytokine release syndrome (CRS).

3. **Clinical Trials**: Hemogenyx has successfully moved HEMO-CAR-T into clinical trials, which means they are testing it on patients with relapsed or refractory FLT3-positive AML. Early results from these trials are promising, indicating that the treatment is safe and may be effective.

4. **Potential for Bone Marrow Transplant**: One of the innovative aspects of HEMO-CAR-T is that it could be used as a conditioning treatment before a bone marrow transplant. This means it could help clear out leukemia cells and prepare the patient's body for receiving new stem cells from a donor, potentially without the need for harsh chemotherapy.

5. **Future Directions**: Hemogenyx is also exploring other treatments, such as a bispecific antibody that targets both FLT3 and another protein, which could provide an alternative to CAR-T therapy. This shows their commitment to finding multiple ways to treat AML effectively.

### Conclusion

In summary, Hemogenyx has made significant progress in developing a new CAR-T therapy for AML that is designed to be safer and more effective than previous attempts. Their innovative approach could not only help treat leukemia but also improve the process of bone marrow transplants, offering hope to patients who have limited treatment options.

"Manufacturing of HG-CT-1 for the treatment of a third patient is currently underway."

That information was in an RNS over a week ago and if it was already mentioned at the AGM, then it is almost 2 weeks old news ( but I am unsure if it was mentioned at the AGM)

As I recall it, the manufacturing of HG-CT-1 takes about 2 weeks, so I think Patient 3 might soon get their shot .

It could potentially happen already this week, but might be more likely to happen next week.

But will it make the share price move north.

I doubt that we are so lucky.

But one day our luck will change.

@Saint68, I assume the 8.6 million shares is if the BOD issue all of the 100 percent they were just allocated at the recent AGM.

(Let's hope that won't be necessary, never the less, good to have the option if ABSOLUTELY needed)

@Bainbo1, your calculations aligns very well with my rudimental head calculations, but don't confuse the value of each of the shares with the share price.

It can be 2 completely different valuations.

There are shares trading at less then their value, when the assets of a company are dived by the number of shares, if I remember correctly this is called intrinsic value.

I hope, should we get a 1 Billion offer, that it is only for HG-CT-1, because if it's for the company we are selling us self to short.

Way to short.

There would be plenty money in the coffer to pay a special dividend.

10 pounds a share would do me just fine:-)

Less then 50 million expenditure for the company and plenty to develop our other candidates.

It's a long-standing pattern and not anything new under the sun that HEMOGENYX needs funds to pay rent, salary and pay for research and clinical trial.

With no income, money has to come from somewhere.

For a company listed on a stock exchange it is kind of the point that you go to the market to fund the company until they can pay for things out of a generated cashflow.

When it comes to medicine everyone knows or should know, that cashflow is years away.

There are a couple of hurdles that has to be overcome first, several phased studies, which can just about be boiled down to safety and efficacy.

And then there is the little tiny issue called funding:-)

My general logical perception on this is that the share price could/should go up on positive news regarding making it to clinical trial.

Safety is established with just even 1 patient

Efficacy is established.

All three has happened, but the market has not acted as I had expected from a logical point of view.

That's my bad luck.

I am thrilled the BOD has managed to raise funds in a market that does not operate as I expected it would.

That is not the same as saying I am happy that it for a long time it had to happen at a discount and the share price kept falling.

Having said that, the main reason I am not happy is because of my huge percentage loss, as I am all in favour of buying these shares cheaply.

It is therefor now a delight to see that discounts are a thing of the past and the company can still manage to get funding on the market.

When we get enough positive data to present, then there will also be a decent if not fantastic deal negotiated, but do far that has not happened.

Patience is all that is needed.

But it is indeed NEEDED

Remember: "Years and Billions"

Several

In a post by Hemotruth earlier today, he wrote the following:

"When this company received FDA clearance the SP got to 7p..now we are down to 0.44p that's a 93% loss"

I haven't done the math regarding where we are in old money or what the loss is, I am happy to take Hemotruth's claim on face value.

And it beggers belief that's were we are after having become a clinical company, having 2 Patients injected with HG-CT-1 and there being no mention worthy detrimental consequences and most importantly signs of efficacy.

I am sure there was none of us who had expected that to be the case (proof is in the pudding, if we had, we would have sold up and bought in again now)

We have all expected that the share price would increase with each achievement and mile stone reached, because we have this idea that is how the market normally acts.

Well, in our case it hasn't.

And for that reason it beggers belief that there are people who thinks it is okay to have a constant go at the BOD.

I am sure they just like anyone else would have liked to have had the funding situation sorted a long time ago and at a much higher price point.

And they have taken steps to try and ensure that.

Unfortunately it has not played out that way.

But despite a market that has not acted as we had expected the BOD has managed to raise capital and there seems to be no appreciation of that.

And it beggers belief.

No point in playing fantasy football and ask people what they would have done and assume it would have played out better.

But there is every point in asking people how big a percentage of HG-CT-1 they were willing to have given up by this stage to another entity to still be at 28 pounds and above (7 pence in old money)

Which would also be dilution, but in another shape.

Clearly there hasn't been an offer on the table that has been worth considering Vs raising money this way despite the discounts that has had to be given.

It is simples, it has not worked out as expected and no one enjoy the share price being this low, incl the BOD.

IT BEGGERS BELIEF TO THINK OTHERWISE